We are live on ! Find out more
PALI icon

Palisade Bio
PALI

11 hedge funds and large institutions have $648K invested in Palisade Bio in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 0 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

3.7% less ownership

Funds ownership: 11.79% → 8.1% (-3.7%)

44% less capital inflows, than outflows

Capital inflows: $435K | Capital outflows: $782K

58% less funds holding

Funds holding: 26 → 11 (-15)

88% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 17

Holders
11
Holders Change
-15
Holders Change %
-57.69%
% of All Funds
0.18%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
6
Reduced
–
Closed
17
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CVI Holdings
CVI Holdings
Delaware
+$155K
2
WAM
Warberg Asset Management
Illinois
+$90.1K
3
Virtu Financial
Virtu Financial
New York
+$70.6K
4
Two Sigma Securities
Two Sigma Securities
New York
+$69.8K
5
Two Sigma Investments
Two Sigma Investments
New York
+$34K

Top Sellers

Rank Fund Capital Flow
1
ACM
Altium Capital Management
New York
-$559K
2
Sargent Investment Group
Sargent Investment Group
Maryland
-$76K
3
Renaissance Technologies
Renaissance Technologies
New York
-$51K
4
SM
Sabby Management
Florida
-$44K
5
Geode Capital Management
Geode Capital Management
Massachusetts
-$12K

PALI Hedge Fund Activity: Q4 2022 in Review

11 of the 6,243 institutional investors tracked by Wall St. Rank reported a position in Palisade Bio (PALI) for Q4 2022, worth a combined $648K — down 23% from $842K a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of PALI and 2 opened new positions — a net loss of 15 holders — while 0 trimmed existing stakes and 6 added.

The largest buyer was CVI Holdings, opening a new position worth an estimated $155K. The largest seller was Altium Capital Management, exiting entirely with an estimated $559K sold.

  • 11 institutional investors held Palisade Bio (PALI) as of Q4 2022, down from 26 in Q3 2022.
  • Funds reported $648K of Palisade Bio stock for Q4 2022, down 23% quarter-over-quarter.
  • 2 funds opened new Palisade Bio positions in Q4 2022 and 17 closed out, a net change of -15 holders.
  • The largest Palisade Bio buyer in Q4 2022 was CVI Holdings, an estimated $155K added.
  • The largest Palisade Bio seller in Q4 2022 was Altium Capital Management, an estimated $559K sold.

Based on aggregated 13F filings for Q4 2022.